Confirm delete?

Bertin Bioreagent
logo

Search

Contact Us

GLP SAM-Screener™ Assay Kit

  • Zoom
    GLP SAM-<wbr/>Screener™ Assay Kit
  • GLP SAM-<wbr/>Screener™ Assay Kit
Cat No: 600570
Assays - Miscellaneous
Cayman
€461.00
Price is excluding VAT and does not include packaging neither shipping

Most histone lysine methyltransferases contain a conserved domain (SET) that utilizes S-adenosyl-L-methionine (SAM or AdoMet) as a co-factor to catalyze the methylation of the epsilon amino group of lysine. G9a-like protein (GLP) is a SET domain-contai...

More

This product can only be bought through Cayman Chemical. Please contact us.

- +
Territorial Availability: Available through Bertin Technologies only in Europe
Technical Warning: Check the Additional Items Required section of this kit booklet to verify if UltraPure Water (Milli-Q or equivalent) is needed for this assay
Synonyms:
Product Overview:
Most histone lysine methyltransferases contain a conserved domain (SET) that utilizes S-adenosyl-L-methionine (SAM or AdoMet) as a co-factor to catalyze the methylation of the epsilon amino group of lysine. G9a-like protein (GLP) is a SET domain-containing methyltransferase that specifically mono- and di-methylates histone H3 at lysine 9 (H3K9). GLP and G9a function as major euchromatic H3K9me1 and H3K9me2 histone methyltransferases and also have been found to methylate several nonhistone substrates, including p53(K372). This fluorescence polarization assay is based upon a proprietary small molecule fluorescent probe that binds to the SAM binding pocket in GLP. Binding of the small molecule probe to GLP induces an increase in fluorescence polarization. Binding of the probe can be competed with the endogenous cofactor SAM or by the inhibitor sinefungin, but is unaffected by the histone H3 peptide substrate. The GLP SAM-Screener Assay is robust (Z' >0.5) and exhibits a greater than 100 mP shift over a range of 0-250 nM GLP. The assay is suitable for high-throughput screening in the provided 384-well plate or can be scaled to higher density plate formats (e.g., 1,536-well) if desired.
Most histone lysine methyltransferases contain a conserved domain (SET) that utilizes S-adenosyl-L-methionine (SAM or AdoMet) as a co-factor to catalyze the methylation of the epsilon amino group of lysine. G9a-like protein (GLP) is a SET domain-containing methyltransferase that specifically mono- and di-methylates histone H3 at lysine 9 (H3K9). GLP and G9a function as major euchromatic H3K9me1 and H3K9me2 histone methyltransferases and also have been found to methylate several nonhistone substrates, including p53(K372). This fluorescence polarization assay is based upon a proprietary small molecule fluorescent probe* that binds to the SAM binding pocket in GLP. Binding of the small molecule probe to GLP induces an increase in fluorescence polarization. Binding of the probe can be competed with the endogenous cofactor SAM or by the inhibitor sinefungin, but is unaffected by the histone H3 peptide substrate. The GLP SAM-Screener™ Assay is robust (Z' >0.5) and exhibits a greater than 100 mP shift over a range of 0-250 nM GLP. The assay is suitable for high-throughput screening in the provided 384-well plate or can be scaled to higher density plate formats (e.g., 1,536-well) if desired. *United States Patent 9,120,820
Size: 384 wells
Shipping: dry ice
Stability: Store at -80 degrees; shelf life 365 days maximum after production
Custom Code: 3822000002
UNSPSC code: 41116104

Shinkai, Y., and Tachibana, M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 25 781-788 (2011).

Wu, H., Min, J., Lunin, V.V., et al. Structural biology of human H3K9 methyltransferases. PLoS One 5(1) e8570 (2010).

Bannister, A.J., and

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : GLP SAM-<wbr/>Screener™ Assay Kit There are 4 products.